PatientsVille.com Logo

Prophylaxis and Verorab

PatientsVille

Prophylaxis Symptoms and Causes

In the early 1980s, when the HIV/AIDS epidemic began, patients rarely lived longer than a few years. But today, there are many effective medicines to fight the infection, and people with HIV have longer, healthier lives.

There are five major types of medicines:

  • Reverse transcriptase (RT) inhibitors - interfere with a critical step during the HIV life cycle and keep the virus from making copies of itself
  • Protease inhibitors - interfere with a protein that HIV uses to make infectious viral particles
  • Fusion inhibitors - block the virus from entering the body's cells
  • Integrase inhibitors - block an enzyme HIV needs to make copies of itself
  • Multidrug combinations - combine two or more different types of drugs into one

These medicines help people with HIV, but they are not perfect. They do not cure HIV/AIDS. People with HIV infection still have the virus in their bodies. They can still spread HIV to others through unprotected sex and needle sharing, even when they are taking their medicines.

NIH: National Institute of Allergy and Infectious Diseases

Check out the latest treatments for prophylaxis

prophylaxis treatment research studies

Verorab clinical trials, surveys and public health registries


Find Drug Side Effect reports



Verorab Side Effects

Rabies (37)
Pruritus (27)
Pyrexia (14)
Nausea (7)
Dehydration (5)
Hydrophobia (4)
Fear (4)
Convulsion (4)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Prophylaxis Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen
Condition: Rabies
Interventions: Biological: Purified Vero cell Rabies Vaccine (PVRV);   Biological: PVRV + purified Equine Rabies Immunoglobulin (pERIG)
Outcome Measures: Percentage of participants with seroprotection rate following PEP using Verorab® vaccine with or without pERIG Favirab®;   Seroprotection and geometric mean titers (GMTs) following primary and booster vaccination by Verorab® with or without Favirab® infiltration;   Occurrence and intensity of solicited injection site and systemic reactions and unsolicited adverse event s occurring after vaccination with Verorab® vaccine, with or without pERIG Favirab®
2 Unknown  Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine
Condition: Malaria
Interventions: Biological: MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP;   Biological: Verorab vaccine
Outcome Measures: Number of clinical malaria episodes occurring during the consecutive malaria transmission season after the third vaccination;   Solicited adverse events measured from day 0 to day 7 after each dose;   Unsolicited adverse events measured up to one month after each dose;   Serious Adverse Events measured during the 12 months of study duration;   The humoral response to the vaccine antigen: assessed by measuring the level of IgG by ELISA;   IgG ability to recognize the native protein on Merozoite using Western Blot(WB) method;   Incidence of all clinical malaria episodes occurring through two transmission seasons subsequent to the 3 doses.
3 Unknown  Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG
Conditions: Rabies;   Vaccine
Intervention: Biological: SPEEDA and TRCS SPEEDA
Outcome Measures: immunogenicity (the level of rabies neutralizing antibodies by RFFIT test);   safety
4 Unknown  Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine
Condition: Malaria
Interventions: Biological: GMZ2 (malaria vaccine);   Biological: GMZ2 malaria vaccine;   Biological: Verorab vaccine
Outcome Measures: Local and systemic reactogenicity;   Unsolicited adverse events;   Occurrence of serious adverse events;   Biological safety;   Humoral immune response to GLURP and MSP 3;   Cellural immune response